Yakult's Japan Duvelisib Decision Casts New Shadow Over Shrinking Pharma Ops
Generics Already A Major Challenge
Yakult’s decision to pull an approval application for duvelisib in Japan came shortly after a FDA advisory committee said it would re-evaluate the safety and efficacy of the PI3K inhibitor four years since its approval. The developments cast a new shadow over Yakult’s already-suffering pharmaceutical business.
